Table 5. Baseline characteristics of patients with long-term OS (i.e., OS ⩾30 months).

Characteristic	Long-term OS (n=215)	Non-long-term OS (n=844)	P-value
Ethnic origin, %
White	94	81	0.0002a
Non-white	6	15
Missing	0	5
Risk factors based on published MSKCC data, %b
0 (favourable)	70	31	<0.0001c
1–2 (intermediate)	28	42
⩾3 (poor)	0	5
Missing	1	21
ECOG PS, %d
0	75	58	<0.0001c
1	25	40
2	0	3
Prior nephrectomy, %
Yes	96	74	<0.0001a
No	4	19
Missing	0	7
Prior cytokine, %
Yes	21	29	0.0170a
No	79	71
Missing	0	<1
Baseline Hgb, %d
⩽LLN	22	44	<0.0001a
>LLN	78	56
Missing	0	<1
Baseline LDH, %d
>1.5 × ULN	3	7	0.0078a
⩽1.5 × ULN	96	78
Missing	1	15
Baseline-corrected Ca, %d
>10 mg dl−1	5	19	<0.0001a
⩽10 mg dl−1	95	80
Missing	0	1
Baseline neutrophils, %
⩽ULN	97	78	<0.0001e
>ULN	2	12
Missing	1	10
Baseline platelets, %
⩽ULN	96	80	<0.0001a
>ULN	4	19
Missing	0	<1

Abbreviations: Ca=calcium; ECOG PS=Eastern Cooperative Oncology Group performance status; Hgb=haemoglobin; LDH=lactate dehydrogenase.

^aPearson χ² test for general association.

^bIncludes low serum haemoglobin level; elevated corrected serum calcium level; elevated serum lactate dehydrogenase level; poor performance status; and interval of <1 year between diagnosis and sunitinib treatment (Motzer et al, 2002).

^cMantel–Haenszel χ² test for general association.

^dRisk factor included in the MSKCC prognostic model (Motzer et al, 2002).

^eFisher's exact test for general association when sample size requirement of the χ² test is not met.